Navigation Links
Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
Date:11/28/2008

d respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process. Encorium is headquartered in Wayne, Pennsylvania with its European base of operations in Espoo, Finland. The Company has a geographic footprint that includes over one billion people in North America, Western/Central/Eastern Europe, Scandinavia, and the Baltics.

This press release contains forward-looking statements identified by words such as "estimate," "project," "expect," "intend," "believe," "anticipate" and similar expressions regarding future expectations. Those statements involve risks and uncertainties, and actual results could differ materially from those discussed. Risks and uncertainties that could affect the Company's future operating results and financial condition generally include, without limitation: (i) our success in attracting new business and retaining existing clients and projects; (ii) the size, duration, and timing of clinical trials we are currently managing may change unexpectedly; (iii) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (iv) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (v) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vi) the ability to maintain profit margins in a competitive marketplace; (vii) our ability to attract and retain qualified personnel; (viii) the sensitivity of our business to general economic conditions; (ix) other economic, competitive, governmental and technological factors affecting our operations, markets, products,
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Rancho BioSciences , the ... manually curated public data source TCGA for ... the data is now available for other oncology groups. ... and internal data sources for their Pharma, Government and ... the data that becomes more easily accessible. Rancho ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Whitehouse Laboratories ... its ICH Stability Testing and Package Test Capacity. Responding ... centers on a dramatic increase in environmental chamber storage ... stability, storage and aging samples to be securely held ... this major capital expenditure has already taken place with ...
(Date:10/30/2014)... Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), ... present a company overview at the Nomura Biotechnology Conference on ... Boston, MA. A live webcast ... Media" section of the Company,s website, www.isispharm.com .  A ... hours and will be archived for a limited time. ...
(Date:10/30/2014)... challenges in the development of quantum technologies has been ... paper published today (28 October) in Nature Communications ... make a new type of flexibly designed microscopic trap ... sensors and specialised superfast computers, often depend on harnessing ... trapping these tiny particles are hugely problematic because of ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and ... announced that a supplemental New Drug Application (sNDA) has been ... the expanded use of BYETTA® (exenatide) injection as an add-on ... thiazolidinedione (TZD) in conjunction with diet and exercise for adults ...
... 22, 2010 Novavax, Inc. (Nasdaq: NVAX ... School, led by Dr. Trudy Morrison, published in the ... report indicating that a novel virus-like particle (VLP) vaccine ... a live virus challenge.  This vaccine candidate has been ...
... the University of Santiago de Compostela (USC) have analysed levels ... in Galicia. The results show that 34% of these schools ... Union. Excessive inhalation of radon is associated with lung cancer. ... taken, 34% had radon levels in excess of 400 Bequerels/m3 ...
Cached Biology Technology:Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 2Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 3Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 4Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 5Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 6Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 7NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 2NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 3NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 434 percent of Galician secondary schools exceed maximum recommended radon levels 2
(Date:10/30/2014)... 2014 Biological membranes are mainly composed of lipid ... solution ions onto lipid membranes helps clarify functional ... provides a quantitative description of the equilibria between ... and Zbigniew Figaszewski from the University of Bialystok, ... these findings, just published in EPJ E ...
(Date:10/29/2014)... released by unconventional oil and gas production are well ... in the open access journal Environmental Health . ... found. The study is the first to be based ... sites and could be used to supplement official air-quality ... reserves that do not readily flow to the surface. ...
(Date:10/29/2014)... In the largest study of its kind to date, ... genes that heighten the risk for autism. Joseph Buxbaum, ... York City, Mark Daly, Ph.D., Broad Institute of Harvard ... DNA samples from affected children, parents and unrelated people. ... to contribute to the risk for autism spectrum disorder ...
Breaking Biology News(10 mins):Ion adsorption matter in biology 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3
... BiOptix announced continued support of the Colorado BioScience ... life sciences showcase event in Colorado to be ... continues to believe in the goals and community that is ... President and CEO of BiOptix.   "As Colorado continues to ...
... become more severe in the Southwest, trees are increasingly ... to middle elevations, University of Arizona researchers report in ... Journal of Geophysical Research Biogeosciences ., Lead author Jeremy ... of geosciences, said: "We know the climate in the ...
... study provides a first-time analysis of the value of forage ... and anchovies. Three kinds of contributions of forage fish were ... fish, and as an important link in the food web ... a total of $16.9 billion, as both direct catch and ...
Cached Biology News:BiOptix Participates in Leading Life Sciences Event BioWest 2012 2Droughts are pushing trees to the limit 2Droughts are pushing trees to the limit 3Droughts are pushing trees to the limit 4Study provides first-time analysis of 3 distinct contributions of forage fish worldwide 2Study provides first-time analysis of 3 distinct contributions of forage fish worldwide 3
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
... --- a cocktail of 3 siRNAs specifically ... our most popular product. The siTrio reagent ... of your target gene when used under ... and confirmation of optimal transfection with one ...
... with 96 x 0.2 ml reaction module ... applications. It is equipped with an interchangeable ... is compatible with optical modules for real-time ... by algorithm, block, or in-sample probe. It ...
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
Biology Products: